User: Guest

CYSTIC FIBROSIS \THERAPEUTICS

Global Market Trajectory & Analytics

MCP-6233

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3562

Interactions with Platform & by Email *

INTERACTIONS

641

Unique # Participated *

PARTICIPANTS

107

Responses Validated *

VALIDATIONS

48

* Login to view program details and full enterprise executive list.

  •  DATE

    JULY 2020

  •  TABLES

    111

  •  PAGES

    197

  •  EDITION

    16

  •  PRICE

    USD $5450

COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Cystic Fibrosis \Therapeutics estimated at US$5.9 Billion in the year 2020, is projected to reach a revised size of US$13.2 Billion by 2027, growing at a CAGR of 12.2% over the analysis period 2020-2027. Medication, one of the segments analyzed in the report, is projected to record a 13.1% CAGR and reach US$9.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Devices segment is readjusted to a revised 10.4% CAGR for the next 7-year period.
The Cystic Fibrosis \Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2027 trailing a CAGR of 16.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 10.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.
In the global Other Treatment Methods segment, USA, Canada, Japan, China and Europe will drive the 9.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$519.3 Million in the year 2020 will reach a projected size of US$957 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.9 Billion by the year 2027, while Latin America will expand at a 11.2% CAGR through the analysis period. We bring years of research experience to this 16th edition of our report. The 197-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, AbbVie Inc.; Galapagos NV; Genentech; Gilead Sciences Inc.; Novartis AG; Vertex Pharmaceuticals Inc.
» Treatment Method (Medication, Devices, Other Treatment Methods)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL